Benzofuranylpropylaminopentane (BPAP, (-)-BPAP,[1]BFPAPn, or BFPAP) is a drug with an unusual effects profile. It can loosely be grouped with the stimulant or antidepressant drug families, but its mechanism of action is quite different.[2][3]
BPAP (along with another similar compound PPAP) is classified as a catecholaminergic and serotonergic activity enhancer. This means that it stimulates the impulse propagation mediated transmitter release of the neurotransmittersdopamine, norepinephrine and serotonin in the brain. However, unlike stimulant drugs like amphetamine, which release a flood of these neurotransmitters in an uncontrolled manner, BPAP instead only increases the amount of neurotransmitter that gets released when a neuron is stimulated by receiving an impulse from a neighbouring neuron. So while both amphetamine and BPAP increase the amount of neurotransmitters that get released, amphetamine causes neurons to dump neurotransmitter stores into the synapse regardless of external input, while with BPAP the pattern of neurotransmitter release is not changed, but when the neuron would normally release neurotransmitter, a larger amount than normal is released.[4][5]
^Shimazu S, Takahata K, Katsuki H, Tsunekawa H, Tanigawa A, Yoneda F, et al. (June 2001). "(-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release". European Journal of Pharmacology. 421 (3): 181–9. doi:10.1016/S0014-2999(01)01040-8. PMID11516435.
^Shimazu S, Tsunekawa H, Yoneda F, Katsuki H, Akaike A, Janowsky A (December 2003). "Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane". European Journal of Pharmacology. 482 (1–3): 9–16. doi:10.1016/j.ejphar.2003.09.044. PMID14659999.
^Magyar K, Lengyel J, Bolehovszky A, Knoll B, Miklya I, Knoll J (2002). "The fate of (-)1-(benzofuran-2-yl)-2-propylaminopentane . HCl, (-)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain". European Journal of Drug Metabolism and Pharmacokinetics. 27 (3): 157–61. doi:10.1007/BF03190451. PMID12365195. S2CID30618267.
^Oka T, Yasusa T, Ando T, Watanabe M, Yoneda F, Ishida T, Knoll J (May 2001). "Enantioselective synthesis and absolute configuration of (-)-1-(benzofuran-2-yl)-2-propylaminopentane, ((-)-BPAP), a highly potent and selective catecholaminergic activity enhancer". Bioorganic & Medicinal Chemistry. 9 (5): 1213–9. doi:10.1016/S0968-0896(00)00341-2. PMID11377179.
^Shimazu S, Miklya I (May 2004). "Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28 (3): 421–7. doi:10.1016/j.pnpbp.2003.11.016. PMID15093948. S2CID37564231.
^Gaszner P, Miklya I (January 2006). "Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 30 (1): 5–14. doi:10.1016/j.pnpbp.2005.06.004. PMID16023777. S2CID26570703.
